Latest Breaking News On - துறை ஆஃப் தி ஆரோக்கியம் - Page 8 : comparemela.com

U.S. Department of Defense Department of the Health and Human Services (HHS) and the Department of Defense (DOD) jointly announced an agreement with Merck to support advanced development and large-scale manufacturing of the their investigational therapeutic MK-7110 to treat hospitalized patients with severe or critical COVID-19. The investigational therapeutic is a promising first-in-class fusion protein and immune modulator. Immune modulators have the potential to minimize the damaging effects of an overactive immune response to COVID-19. This overactive response can contribute to the severity of the illness. “Our agreement with Merck is the latest example of how industry and government are coming together under Operation Warp Speed to move potential therapeutics all the way from development through to manufacturing, enabling faster distribution,” said HHS Secretary Alex Azar.

United statesAlex azarDepartment of defenseBiomedical advanced researchHuman servicesDrug administrationProgram executive office for chemicalDevelopment authorityDepartment of the healthArmy contracting commandDepartment of healthOffice of theNuclear defenseOperation warp speedPresident trumpOperation warp speed supported